{"id":8124,"date":"2023-01-05T16:23:53","date_gmt":"2023-01-05T15:23:53","guid":{"rendered":"http:\/\/www.seventure.fr\/?p=8124"},"modified":"2023-07-24T16:25:57","modified_gmt":"2023-07-24T14:25:57","slug":"domain-therapeutics-announces-first-patient-dosed-with-dt-9081-in-phase-i-clinical-study-in-patients-with-advanced-recurrent-or-metastatic-solid-tumors-the-eprad-study","status":"publish","type":"post","link":"https:\/\/www.seventure.fr\/en\/domain-therapeutics-announces-first-patient-dosed-with-dt-9081-in-phase-i-clinical-study-in-patients-with-advanced-recurrent-or-metastatic-solid-tumors-the-eprad-study\/","title":{"rendered":"Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study in patients with advanced, recurrent or metastatic solid tumors: the EPRAD study"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[101,106],"tags":[],"class_list":["post-8124","post","type-post","status-publish","format-standard","hentry","category-life-sciences-en","category-biotech-pharmaceuticals"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study in patients with advanced, recurrent or metastatic solid tumors: the EPRAD study | Seventure<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.seventure.fr\/en\/domain-therapeutics-announces-first-patient-dosed-with-dt-9081-in-phase-i-clinical-study-in-patients-with-advanced-recurrent-or-metastatic-solid-tumors-the-eprad-study\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ana Salas\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.seventure.fr\/en\/domain-therapeutics-announces-first-patient-dosed-with-dt-9081-in-phase-i-clinical-study-in-patients-with-advanced-recurrent-or-metastatic-solid-tumors-the-eprad-study\/\",\"url\":\"https:\/\/www.seventure.fr\/en\/domain-therapeutics-announces-first-patient-dosed-with-dt-9081-in-phase-i-clinical-study-in-patients-with-advanced-recurrent-or-metastatic-solid-tumors-the-eprad-study\/\",\"name\":\"Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study in patients with advanced, recurrent or metastatic solid tumors: the EPRAD study | Seventure\",\"isPartOf\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\"},\"datePublished\":\"2023-01-05T15:23:53+00:00\",\"dateModified\":\"2023-07-24T14:25:57+00:00\",\"author\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/f946a5619a12f5415e660b8de142e495\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/domain-therapeutics-announces-first-patient-dosed-with-dt-9081-in-phase-i-clinical-study-in-patients-with-advanced-recurrent-or-metastatic-solid-tumors-the-eprad-study\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.seventure.fr\/en\/domain-therapeutics-announces-first-patient-dosed-with-dt-9081-in-phase-i-clinical-study-in-patients-with-advanced-recurrent-or-metastatic-solid-tumors-the-eprad-study\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.seventure.fr\/en\/domain-therapeutics-announces-first-patient-dosed-with-dt-9081-in-phase-i-clinical-study-in-patients-with-advanced-recurrent-or-metastatic-solid-tumors-the-eprad-study\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.seventure.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study in patients with advanced, recurrent or metastatic solid tumors: the EPRAD study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\",\"url\":\"https:\/\/www.seventure.fr\/en\/\",\"name\":\"Seventure\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.seventure.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/f946a5619a12f5415e660b8de142e495\",\"name\":\"Ana Salas\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d6bd15ac43de868d8defc5e4c6f7146da38bec786e08467e81680cd5ac0a24d5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d6bd15ac43de868d8defc5e4c6f7146da38bec786e08467e81680cd5ac0a24d5?s=96&d=mm&r=g\",\"caption\":\"Ana Salas\"},\"url\":\"https:\/\/www.seventure.fr\/en\/author\/ana-salas\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study in patients with advanced, recurrent or metastatic solid tumors: the EPRAD study | Seventure","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.seventure.fr\/en\/domain-therapeutics-announces-first-patient-dosed-with-dt-9081-in-phase-i-clinical-study-in-patients-with-advanced-recurrent-or-metastatic-solid-tumors-the-eprad-study\/","twitter_misc":{"Written by":"Ana Salas"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.seventure.fr\/en\/domain-therapeutics-announces-first-patient-dosed-with-dt-9081-in-phase-i-clinical-study-in-patients-with-advanced-recurrent-or-metastatic-solid-tumors-the-eprad-study\/","url":"https:\/\/www.seventure.fr\/en\/domain-therapeutics-announces-first-patient-dosed-with-dt-9081-in-phase-i-clinical-study-in-patients-with-advanced-recurrent-or-metastatic-solid-tumors-the-eprad-study\/","name":"Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study in patients with advanced, recurrent or metastatic solid tumors: the EPRAD study | Seventure","isPartOf":{"@id":"https:\/\/www.seventure.fr\/en\/#website"},"datePublished":"2023-01-05T15:23:53+00:00","dateModified":"2023-07-24T14:25:57+00:00","author":{"@id":"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/f946a5619a12f5415e660b8de142e495"},"breadcrumb":{"@id":"https:\/\/www.seventure.fr\/en\/domain-therapeutics-announces-first-patient-dosed-with-dt-9081-in-phase-i-clinical-study-in-patients-with-advanced-recurrent-or-metastatic-solid-tumors-the-eprad-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.seventure.fr\/en\/domain-therapeutics-announces-first-patient-dosed-with-dt-9081-in-phase-i-clinical-study-in-patients-with-advanced-recurrent-or-metastatic-solid-tumors-the-eprad-study\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.seventure.fr\/en\/domain-therapeutics-announces-first-patient-dosed-with-dt-9081-in-phase-i-clinical-study-in-patients-with-advanced-recurrent-or-metastatic-solid-tumors-the-eprad-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.seventure.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study in patients with advanced, recurrent or metastatic solid tumors: the EPRAD study"}]},{"@type":"WebSite","@id":"https:\/\/www.seventure.fr\/en\/#website","url":"https:\/\/www.seventure.fr\/en\/","name":"Seventure","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.seventure.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/f946a5619a12f5415e660b8de142e495","name":"Ana Salas","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d6bd15ac43de868d8defc5e4c6f7146da38bec786e08467e81680cd5ac0a24d5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d6bd15ac43de868d8defc5e4c6f7146da38bec786e08467e81680cd5ac0a24d5?s=96&d=mm&r=g","caption":"Ana Salas"},"url":"https:\/\/www.seventure.fr\/en\/author\/ana-salas\/"}]}},"_links":{"self":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts\/8124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/comments?post=8124"}],"version-history":[{"count":1,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts\/8124\/revisions"}],"predecessor-version":[{"id":8127,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts\/8124\/revisions\/8127"}],"wp:attachment":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media?parent=8124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/categories?post=8124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/tags?post=8124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}